ABN Amro Investment Solutions Invests $151,000 in Repligen Corporation $RGEN

ABN Amro Investment Solutions acquired a new stake in Repligen Corporation (NASDAQ:RGEN) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 150,000 shares of the biotechnology company’s stock, valued at approximately $151,000. ABN Amro Investment Solutions owned about 0.27% of Repligen as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Hantz Financial Services Inc. boosted its position in shares of Repligen by 2,663.6% in the 2nd quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 293 shares during the last quarter. CWM LLC lifted its stake in Repligen by 67.2% in the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 135 shares during the period. Center for Financial Planning Inc. boosted its holdings in Repligen by 34.2% during the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock worth $61,000 after buying an additional 126 shares during the last quarter. Trust Co. of Vermont acquired a new position in shares of Repligen during the 3rd quarter worth about $67,000. Finally, Wilmington Savings Fund Society FSB increased its stake in shares of Repligen by 2,750.0% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 495 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Weiss Ratings cut shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, January 30th. Wells Fargo & Company boosted their price target on shares of Repligen from $175.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, December 15th. UBS Group upped their price objective on shares of Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Canaccord Genuity Group lifted their target price on Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a report on Wednesday, October 29th. Finally, Jefferies Financial Group set a $160.00 price target on shares of Repligen and gave the company a “hold” rating in a report on Tuesday, October 28th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $177.92.

Repligen Price Performance

NASDAQ:RGEN opened at $135.41 on Wednesday. Repligen Corporation has a one year low of $102.96 and a one year high of $175.77. The company has a market cap of $7.62 billion, a P/E ratio of 6,773.89, a P/E/G ratio of 2.49 and a beta of 1.13. The firm’s fifty day moving average price is $158.24 and its two-hundred day moving average price is $146.09. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.36 and a quick ratio of 7.14.

Insider Buying and Selling

In other news, Director Karen A. Dawes sold 275 shares of the business’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the sale, the director owned 91,821 shares of the company’s stock, valued at approximately $14,783,181. The trade was a 0.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by corporate insiders.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.